This conversion might result in character translation or format errors in the HTML version. URL addresses listed in MMWR were current as ofĪll HTML versions of MMWR articles are generated from final proofs through an automated process. Provided as a service to MMWR readers and do not constitute or implyĮndorsement of these organizations or their programs by CDC or the U.S.ĭepartment of Health and Human Services. References to non-CDC sites on the Internet are Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration 2019. FDA clears new indications for existing Lyme disease tests that may help streamline diagnoses. CrossRef external icon PubMed external icon Collection and characterization of samples for establishment of a serum repository for Lyme disease diagnostic test development and evaluation. Notice to readers: recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. Washington, DC: Association of State and Territorial Public Health Laboratory Directors 1994. In: proceedings of the Second National Conference on Serologic Diagnosis of Lyme Disease October 27–29, 1994 Dearborn, MI. Association of State and Territorial Public Health Laboratory Directors.Clearance by FDA of the new Lyme disease assays indicates that test performance has been evaluated and is “substantially equivalent to or better than” a legally marketed predicate test. The modified methodology uses a second EIA in place of a western immunoblot assay. On July 29, 2019, FDA cleared several Lyme disease serologic assays with new indications for use based on a modified two-test methodology ( 4). To assist serologic test developers, CDC has made available, with support from NIH, a comprehensive panel of sera from patients with various stages of Lyme disease and other conditions, as well as healthy persons ( 3). Regarding the development of future tests, the report advised that evaluation of new serologic assays include blind testing against a comprehensive challenge panel, and that new assays should only be recommended if their specificity, sensitivity, and precision equaled or surpassed the performance of tests used in the recommended two-test procedure. The conference proceedings recommended a two-test methodology using a sensitive enzyme immunoassay (EIA) or immunofluorescence assay as a first test, followed by a western immunoblot assay for specimens yielding positive or equivocal results ( 1, 2). In 1994, the Association of State and Territorial Public Health Laboratory Directors, CDC, the Food and Drug Administration (FDA), the National Institutes of Health (NIH), the Council of State and Territorial Epidemiologists, and the National Committee for Clinical Laboratory Standards convened the Second National Conference on Serologic Diagnosis of Lyme Disease ( 1). Unacceptable Conditions: CSF or plasma, Contaminated, heat-inactivated, hemolyzed, or severely lipemic specimens.Lyme disease is a tickborne zoonosis for which serologic testing is the principal means of laboratory diagnosis. ![]() Please submit requests for appropriate Western blot testing within 10 days. ![]() IgM Western blot in the chronic stage is not recommended and does not aid in the diagnosis of neuroborreliosis or chronic Lyme disease. Only IgG Western blot should be performed on specimens greater than four weeks after disease onset. Both IgM and IgG Western blots should be performed on specimens less than four weeks after appearance of erythema migrans. Notes: Currently CDC recommendations for the serologic diagnosis of Lyme disease are to screen with a polyvalent EIA test and confirm equivocal and positive with Western blot.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |